TREK-1 (K2P2.1) K+ channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control
Patrick Lugenbiel(Heidelberg University), Dierk Thomas(Heidelberg University), Pascal Geschwill, Arjang Ruhparwar(Essen University Hospital), Claudia Seyler(Heidelberg University), Katharina Govorov(Heidelberg University), Pascal Syren(Heidelberg University), Hugo A. Katus(Heidelberg University), Fabian Wenz(Heidelberg University), Tanja Weis(Heidelberg University), Jennifer Franke(Heidelberg University), Bastian Schmack(Heidelberg University), Patrick A. Schweizer(Goethe University Frankfurt), Claus Bruehl(Heinrich Heine University Düsseldorf), Derk Frank(Schmerzklinik Kiel), Matthias Karck(Heidelberg University), Norbert Frey(University Hospital Schleswig-Holstein)
Cited by 48
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
|European Heart Journal|2020|1.8k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
European Society of Cardiology: cardiovascular disease statistics 2021
|European Heart Journal|2021|1.1k
Myocardial infarction accelerates atherosclerosis
|Nature|2012|1.1k